Abstract

BackgroundPancreatic cancer is among the most lethal malignancies worldwide. This study aimed to identify a novel prognostic biomarker, facilitating treatment selection, using mass spectrometry (MS)-based proteomic analysis with formalin-fixed paraffin-embedded (FFPE) tissue.ResultsThe two groups with poor prognosis (n = 4) and with better prognosis (n = 4) had been carefully chosen among 96 resected cases of pancreatic cancer during 1998 to 2007 in Tohoku University Hospital. Although those 2 groups had adjusted background (UICC-Stage IIB, Grade2, R0, gemcitabine adjuvant), there was a significant difference in postoperative mean survival time (poor 21.0 months, better 58.1 months, P = 0.0067). Cancerous epithelial cells collected from FFPE tissue sections by laser micro-dissection (LMD) were processed for liquid chromatography-tandem mass spectrometry (LC-MS/MS). In total, 1099 unique proteins were identified and 6 proteins showed different expressions in the 2 groups by semi-quantitative comparison. Among these 6 proteins, we focused on Nm23/Nucleoside Diphosphate Kinase A (NDPK-A) and immunohistochemically confirmed its expression in the cohort of 96 cases. Kaplan-Meier analysis showed high Nm23/NDPK-A expression to correlate with significantly worse overall survival (P = 0.0103). Moreover, in the multivariate Cox regression model, Nm23/NDPK-A over-expression remained an independent predictor of poor survival with a hazard ratio of 1.97 (95% CI 1.16-3.56, P = 0.0110).ConclusionsWe identified 6 candidate prognostic markers for postoperative pancreatic cancer using FFPE tissues and immunohistochemically demonstrated high Nm23/NDPK-A expression to be a useful prognostic marker for pancreatic cancer.

Highlights

  • Pancreatic cancer is among the most lethal malignancies worldwide

  • We identified that ADP-ribosylation factor 4 (ARF4), Collagen alpha-3 (VI) chain (CO6A3), DNA-binding protein A (DBPA), Malate dehydrogenase, cytoplasmic (MDHC), Nucleoside diphosphate kinase A (NDKA) and Probable transcription factor PML (PML) were differentially expressed in the 2 groups, including 4 and 2 over-expressed proteins in the poor and better prognostic groups, respectively (Table 2)

  • Though we confirmed all 6 candidate proteins, we focused on Nm23/Nucleoside Diphosphate Kinase A (NDPK-A) because its immunohistochemical results were most compatible with those of spectral counting analysis

Read more

Summary

Introduction

Pancreatic cancer is among the most lethal malignancies worldwide. This study aimed to identify a novel prognostic biomarker, facilitating treatment selection, using mass spectrometry (MS)-based proteomic analysis with formalin-fixed paraffin-embedded (FFPE) tissue. Pancreatic cancer has the worst prognosis of any major malignancy, with a 5-year survival rate of less than 5% after diagnosis [1]. It is the fifth leading cause of cancer death and the incidence of pancreatic cancer is rising in Japan [2,3]. In an effort to explain improved survival rates, several studies have analyzed determinants of long-term survival in postoperative pancreatic cancer patients [6,7,8,9,10,11,12,13,14,15]. There is an urgent need to identify novel molecular targets for early diagnosis and selecting optimal treatments

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call